SANOFI SA INHABER EO 2/ FR0000120578 /
2024-11-08 5:35:55 PM | Chg. +0.22 | Volume | Bid2024-11-08 | Ask2024-11-08 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
95.96EUR | +0.23% | 2,663 Turnover: 255,490.51 |
-Bid Size: - | -Ask Size: - | 120.02 bill.EUR | 3.93% | 22.21 |
GlobeNewswire
09-02
Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to ...
GlobeNewswire
08-26
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadersh...
GlobeNewswire
08-14
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
GlobeNewswire
08-13
Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
08-12
MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter ...
GlobeNewswire
08-08
Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free sur...
GlobeNewswire
08-06
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D ...
GlobeNewswire
08-01
Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
07-31
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2...
GlobeNewswire
07-25
Press Release: Online availability of Sanofi’s half-year financial report for 2024
GlobeNewswire
07-25
Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded
GlobeNewswire
07-24
US Hematologists Express High Unmet Need in Treatments for Warm Autoimmune Hemolytic Anemia and Cold...
GlobeNewswire
07-18
Takeda’s Eohilia Sees Strong Early Adoption and Growth Potential in Eosinophilic Esophagitis, Accord...